Results 331 to 340 of about 21,811,854 (372)
Expression of Cyclooxygenase-1 and Cyclooxygenase-2 in the human prostate [PDF]
Urology, 2000 To determine the cell-specific expression of the two major isoforms of cyclooxygenase (COX-1 and COX-2) in human noncancerous and cancerous prostatic tissues.Thirty-one specimens of prostate carcinoma (CaP) and 10 specimens of benign prostatic hyperplasia (BPH) were stained with mouse antihuman COX-1 and COX-2 monoclonal antibodies.
Pamela D. Unger +6 more
openaire +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Cyclooxygenase-2 and carcinogenesis
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2000Numerous investigations have shown that COX-2 is a participant in the pathway of colon carcinogenesis, especially when mutation of the APC tumor suppressor is the initiating event. Moreover, it seems that the amount of COX-2 is important, since there is a correlation between its level of expression and the size of the tumors and their propensity to ...
Frank A. Fitzpatrick +1 more
openaire +3 more sources
Annual Review of Pharmacology and Toxicology, 1998
▪ Abstract Cyclooxygenase (COX), first purified in 1976 and cloned in 1988, is the key enzyme in the synthesis of prostaglandins (PGs) from arachidonic acid. In 1991, several laboratories identified a product from a second gene with COX activity and called it COX-2.
Y. S. Bakhle +2 more
openaire +3 more sources
▪ Abstract Cyclooxygenase (COX), first purified in 1976 and cloned in 1988, is the key enzyme in the synthesis of prostaglandins (PGs) from arachidonic acid. In 1991, several laboratories identified a product from a second gene with COX activity and called it COX-2.
Y. S. Bakhle +2 more
openaire +3 more sources
Cyclooxygenase 2 and the kidney
Current Opinion in Nephrology and Hypertension, 2001Cyclooxygenase metabolizes arachidonic acid to a family of bioactive fatty acids designated prostaglandins. Two isoforms of cyclooxygenase exist, designated COX1 and COX2. These isoforms are expressed in distinct but important areas of the kidney. COX1 predominates in vascular smooth muscle and collecting ducts, whereas COX2 predominates in the macula ...
Raymond C. Harris, Matthew D. Breyer
openaire +3 more sources
Current Opinion in Internal Medicine, 2006
The purpose of this review is to summarize new information regarding the use of selective inhibitors of the cyclooxygenase-2 enzyme, emphasizing recent developments regarding cardiovascular risk.Selective cyclooxygenase-2 inhibitors are as effective as nonselective nonsteroidal antiinflammatory drugs in relieving pain and inflammation but are ...
Paul Fortun, Christopher J. Hawkey
openaire +3 more sources
The purpose of this review is to summarize new information regarding the use of selective inhibitors of the cyclooxygenase-2 enzyme, emphasizing recent developments regarding cardiovascular risk.Selective cyclooxygenase-2 inhibitors are as effective as nonselective nonsteroidal antiinflammatory drugs in relieving pain and inflammation but are ...
Paul Fortun, Christopher J. Hawkey
openaire +3 more sources
Cyclooxygenase-2 Inhibition and Coagulation
Journal of Cardiovascular Pharmacology, 2006Selective inhibitors of cyclooxygenase-2 (COX-2) have come under scrutiny because of a possibly increased thrombotic risk observed in retrospective studies and comparatively small cancer trials. Indeed, inhibition of COX-2 may favor a prothrombotic environment by suppressing endothelial prostacyclin synthesis while leaving COX-1-dependent platelet ...
Steffel, J +3 more
openaire +4 more sources
Cyclooxygenase-2 and Cancer [PDF]
, 2003 In this review, we summarize studies that initiated further exploration of the relationship of cyclooxygenase-2 (COX-2) to cancer, and evidence for COX-2 involvement in transformation, maintenance of tumor growth, viability, and metastasis. Included are descriptions of the chronic upregulation of COX-2 in multiple human tumors, as well as the ...
Alane T. Koki +3 more
openaire +1 more source
2001
Publisher Summary This chapter deals with aspects of the discovery and development of Cyclooxygenase-2 (Cox-2) inhibitors, which, in the case of rofecoxib, resulted from efforts that were initiated in July of 1992 and culminated in the launch of the drug in the United States in June of 1999. Nonsteroidal antiinflammatory drugs (NSAIDs) have long been
Michael J. Gresser, Alan Nies
openaire +3 more sources
Publisher Summary This chapter deals with aspects of the discovery and development of Cyclooxygenase-2 (Cox-2) inhibitors, which, in the case of rofecoxib, resulted from efforts that were initiated in July of 1992 and culminated in the launch of the drug in the United States in June of 1999. Nonsteroidal antiinflammatory drugs (NSAIDs) have long been
Michael J. Gresser, Alan Nies
openaire +3 more sources
Cyclooxygenase-2 in oncogenesis
Clinica Chimica Acta, 2011Compelling experimental and clinical evidence supports the notion that cyclooxygenase-2, the inducible isoform of cyclooxygenase, plays a crucial role in oncogenesis. Clinical and epidemiological data indicate that aberrant regulation of cyclooxygenase-2 in certain solid tumors and hematological malignancies is associated with adverse clinical outcome.
openaire +2 more sources
Cyclooxygenase-2 and Gastric Cancer
Cancer and Metastasis Reviews, 2011Gastric cancer remains a leading cause of cancer-related deaths worldwide, although its incidence has been steadily declining during recent decades. Expression of cyclooxygenase-2 (COX-2) is elevated in gastric carcinomas and in their precursor lesions.
Johanna Mrena +3 more
openaire +3 more sources